references

Annual Report 2015 - DNDi (16/92)

Annual Report 2015 - DNDi - (1/92)
Annual Report 2015 - DNDi - (2/92)
Annual Report 2015 - DNDi - (3/92)
Annual Report 2015 - DNDi - VISION, MISSION & STRATEGY (4/92)
Annual Report 2015 - DNDi - (5/92)
Annual Report 2015 - DNDi - (6/92)
Annual Report 2015 - DNDi - (7/92)
Annual Report 2015 - DNDi - (8/92)
Annual Report 2015 - DNDi - (9/92)
Annual Report 2015 - DNDi - (10/92)
Annual Report 2015 - DNDi - (11/92)
Annual Report 2015 - DNDi - (12/92)
Annual Report 2015 - DNDi - (13/92)
Annual Report 2015 - DNDi - R&D MODEL & PORTFOLIO (14/92)
Annual Report 2015 - DNDi - (15/92)
Annual Report 2015 - DNDi - (16/92)
Annual Report 2015 - DNDi - (17/92)
Annual Report 2015 - DNDi - (18/92)
Annual Report 2015 - DNDi - (19/92)
Annual Report 2015 - DNDi - (20/92)
Annual Report 2015 - DNDi - (21/92)
Annual Report 2015 - DNDi - (22/92)
Annual Report 2015 - DNDi - (23/92)
Annual Report 2015 - DNDi - (24/92)
Annual Report 2015 - DNDi - (25/92)
Annual Report 2015 - DNDi - (26/92)
Annual Report 2015 - DNDi - (27/92)
Annual Report 2015 - DNDi - (28/92)
Annual Report 2015 - DNDi - (29/92)
Annual Report 2015 - DNDi - (30/92)
Annual Report 2015 - DNDi - (31/92)
Annual Report 2015 - DNDi - (32/92)
Annual Report 2015 - DNDi - (33/92)
Annual Report 2015 - DNDi - (34/92)
Annual Report 2015 - DNDi - (35/92)
Annual Report 2015 - DNDi - (36/92)
Annual Report 2015 - DNDi - (37/92)
Annual Report 2015 - DNDi - (38/92)
Annual Report 2015 - DNDi - (39/92)
Annual Report 2015 - DNDi - (40/92)
Annual Report 2015 - DNDi - (41/92)
Annual Report 2015 - DNDi - (42/92)
Annual Report 2015 - DNDi - (43/92)
Annual Report 2015 - DNDi - (44/92)
Annual Report 2015 - DNDi - (45/92)
Annual Report 2015 - DNDi - (46/92)
Annual Report 2015 - DNDi - (47/92)
Annual Report 2015 - DNDi - (48/92)
Annual Report 2015 - DNDi - (49/92)
Annual Report 2015 - DNDi - (50/92)
Annual Report 2015 - DNDi - (51/92)
Annual Report 2015 - DNDi - (52/92)
Annual Report 2015 - DNDi - (53/92)
Annual Report 2015 - DNDi - (54/92)
Annual Report 2015 - DNDi - (55/92)
Annual Report 2015 - DNDi - STRENGTHENING EXISTING CAPACITIES (56/92)
Annual Report 2015 - DNDi - (57/92)
Annual Report 2015 - DNDi - (58/92)
Annual Report 2015 - DNDi - (59/92)
Annual Report 2015 - DNDi - (60/92)
Annual Report 2015 - DNDi - (61/92)
Annual Report 2015 - DNDi - ADVOCACY, COMMUNICATIONS & FUNDRAISING (62/92)
Annual Report 2015 - DNDi - (63/92)
Annual Report 2015 - DNDi - (64/92)
Annual Report 2015 - DNDi - (65/92)
Annual Report 2015 - DNDi - (66/92)
Annual Report 2015 - DNDi - (67/92)
Annual Report 2015 - DNDi - FINANCIAL REPORT (68/92)
Annual Report 2015 - DNDi - (69/92)
Annual Report 2015 - DNDi - (70/92)
Annual Report 2015 - DNDi - (71/92)
Annual Report 2015 - DNDi - (72/92)
Annual Report 2015 - DNDi - (73/92)
Annual Report 2015 - DNDi - (74/92)
Annual Report 2015 - DNDi - (75/92)
Annual Report 2015 - DNDi - (76/92)
Annual Report 2015 - DNDi - (77/92)
Annual Report 2015 - DNDi - (78/92)
Annual Report 2015 - DNDi - (79/92)
Annual Report 2015 - DNDi - (80/92)
Annual Report 2015 - DNDi - (81/92)
Annual Report 2015 - DNDi - (82/92)
Annual Report 2015 - DNDi - (83/92)
Annual Report 2015 - DNDi - (84/92)
Annual Report 2015 - DNDi - (85/92)
Annual Report 2015 - DNDi - (86/92)
Annual Report 2015 - DNDi - (87/92)
Annual Report 2015 - DNDi - (88/92)
Annual Report 2015 - DNDi - (89/92)
Annual Report 2015 - DNDi - (90/92)
Annual Report 2015 - DNDi - (91/92)
Annual Report 2015 - DNDi - (92/92)

R&D MODEL & PORTFOLIO BUILDING A ROBUST PORTFOLIO DISEASES Screen PROJECTS ARE DIVIDED INTO FIVE CATEGORIES: New treatments (involving NCEs) developed from novel compounds identified through screening, lead optimization, or licensing. These drugs must meet target product profiles (TPPs) and may be used in monotherapy or as part of combination therapies when appropriate. Research Hit to Lead Lead Opt. Pre-clinical Translation Phase I Phase IIa/PoC Development Phase IIb/III Registration Human African Trypanosomiasis SCYX-1330682 SCYX-7158 Fexinidazole SCYX-1608210 Screening Leish H2L Oxaborole Amino pyrazoles DNDI-0690 Fexi/MF combo New Treatments for HIV/VL New Treatments for PKDL VL Treatment Latin America Leishmaniasis CpG-D35 (CL) Anfoleish (CL) New CL combos Screening Chagas H2L New Benz Regimens Chagas Biomarkers Fexinidazole Filaria Screening Macro Filaricide 2 Emodepside Paediatric HIV Two ‘4-in-1’ LPV/r FDC granules LPV/r pellets with dual NRTI FDC Superbooster Therapy Paediatric HIV/TB Hepatitis C Mycetoma New Chemical Entity (NCE); Fexinidazole (for HAT, VL, and Chagas disease) = 1 NCE Sofosbuvir/ Ravidasvir Treatments Fosravuconazole 16 › DNDi Annual Report 2015